Stereological study of neovascularization in temporal arteritis

Journal of Rheumatology

Volumn 33, Issue 10, 2006, Pages 2020-2025

  Nordborg, Claes ^a,b   Larsson, Karolina ^a,b   Nordborg, Elisabeth ^a,b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b Department of Pathology ^*

Author keywords

Endothelial progenitor cell; Giant cell arteritis; Neovascularization; Stereology; Temporal artery

Indexed keywords

PARAFFIN;

ADVENTITIA; AGED; ARTERY MEDIA; ARTERY WALL; ARTICLE; CLINICAL ARTICLE; ENDOTHELIUM CELL; FEMALE; HUMAN; INFLAMMATION; INTIMA; MALE; MICROVASCULARIZATION; MICROVASCULATURE; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; STEM CELL; STEREOMETRY; TEMPORAL ARTERITIS; VASA VASORUM; VASCULAR ENDOTHELIUM;

AGED; AGED, 80 AND OVER; ANTIGENS, CD34; BIOPSY; BLOOD VESSELS; ENDOTHELIUM, VASCULAR; FEMALE; GIANT CELL ARTERITIS; HUMANS; INFLAMMATION; MALE; MICROCIRCULATION; NEOVASCULARIZATION, PATHOLOGIC; STEM CELLS; TEMPORAL ARTERIES; TEMPORAL ARTERITIS; TUNICA INTIMA; TUNICA MEDIA;

EID: 33749996893     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Nordborg E, Nordborg C. Giant cell arteritis: epidemiological clues to its pathogenesis and an update on its treatment. Rheumatology Oxford 2003;42:413-21.
2. Weyand CM, Goronzy JJ. Giant cell arteritis and polymyalgia rheumatica. Ann Intern Med 2003;139:505-15.
3. Weyand CM, Ma-Krupa W, Goronzy JJ. Immunopathways in giant cell arteritis and polymyalgia rheumatica. Autoimmun Rev 2004;3:46-53.
4. Cid MC, Cebrián M, Font C, et al. Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis. Arthritis Rheum 2000;43:184-94.
5. Cid MC, Hernández-Rodríguez J, Esteban M-J, et al. Tissue and serum angiogenetic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis. Circulation 2002;106:1664-71.
6. Hernandez-Rodriguez J, Segarra M, Vilardell C, et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: Angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 2003;107:2428-34.
7. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122-8.
8. Weibel ER. Stereological methods. I. Practical methods for biological morphometry. London: Academic Press; 1979.
9. Riha GM, Lin PH, Lumsden AB, Yao Q, Chen C. Application of stem cells for vascular tissue engineering. Tissue Eng 2005;11:1535-52.
10. Masuda H, Asahara T. Post-natal endothelial progenitor cells for neovascularisation in tissue regeneration. Cardiovasc Res 2003;58:390-8.
11. Hristov M, Erl W, Weber PC. Endothelial progenitor cells. Mobilization, differentiation, and homing. Arterioscler Thromb Vasc Biol 2003;23:1185-9.
12. Hill JM, Zalos G, Halcox JPJ, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003;348:593-600.
13. Asahara T, Kawamoto A. Endothelial progenitor cells for postnatal vasculogenesis. Am J Physiol Cell Physiol 2004;287:C572-C579.
14. Aicher A, Zeiher AM, Dimmeler S. Mobilizing endothelial progenitor cells. Hypertension 2005;45:321-5.
15. Rueda B, Lopez-Nevot MA, Lopez-Diaz MJ, Garcia-Porrua C, Martin J, Gonzalez-Gay MA. A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis. J Rheumatol 2005;32:1737-41.
16. Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003;34:383-94.